Apeloa Pharmaceutical Co.,Ltd Stock

Equities

000739

CNE000000Q45

Pharmaceuticals

End-of-day quote Shenzhen S.E. 06:00:00 2024-05-16 pm EDT 5-day change 1st Jan Change
15.55 CNY -1.77% Intraday chart for Apeloa Pharmaceutical Co.,Ltd -0.58% +1.04%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Sales 2024 * 12.79B 1.77B Sales 2025 * 14.78B 2.05B Capitalization 18.18B 2.52B
Net income 2024 * 1.23B 170M Net income 2025 * 1.59B 220M EV / Sales 2024 * 1.42 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 1.23 x
P/E ratio 2024 *
14.9 x
P/E ratio 2025 *
11.5 x
Employees 7,208
Yield 2024 *
2.27%
Yield 2025 *
3.05%
Free-Float 47.03%
More Fundamentals * Assessed data
Dynamic Chart
1 day-1.77%
1 week-0.58%
Current month+10.21%
1 month+20.54%
3 months+15.19%
6 months-6.44%
Current year+1.04%
More quotes
1 week
15.15
Extreme 15.15
16.15
1 month
12.66
Extreme 12.66
16.15
Current year
10.66
Extreme 10.66
16.15
1 year
10.66
Extreme 10.66
19.99
3 years
10.66
Extreme 10.66
41.87
5 years
8.65
Extreme 8.65
41.87
10 years
4.86
Extreme 4.86
41.87
More quotes
Managers TitleAgeSince
Chief Executive Officer 55 20-01-01
Director of Finance/CFO 49 19-03-06
Chairman 52 -
Members of the board TitleAgeSince
Director/Board Member 58 05-04-14
Director/Board Member 58 20-04-07
Director/Board Member 50 23-04-17
More insiders
Date Price Change Volume
24-05-17 15.55 -1.77% 14,339,210
24-05-16 15.83 +0.25% 16,182,560
24-05-15 15.79 +0.51% 16,118,200
24-05-14 15.71 +2.35% 18,789,620
24-05-13 15.35 -1.85% 22,776,980

End-of-day quote Shenzhen S.E., May 16, 2024

More quotes
Apeloa Pharmaceutical Co Ltd is a China-based company principally engaged in the research and development, production and sales of Active Pharmaceutical Ingredient (API) intermediates, contract development and manufacturing organization (CDMO), preparations and others, as well as import and export trade. The Company operates three businesses. The API intermediates business mainly includes cephalosporin series, penicillin series, psychiatric series, cardiovascular and cerebrovascular series and veterinary API intermediates series. The CDMO business mainly includes research and development services, commercial human drug projects, commercial veterinary drug projects and other commercial products. The preparation business mainly includes anti-infective, cardiovascular and cerebrovascular, psychiatric and anti-tumor preparation products. The Company mainly operates its businesses in domestic and overseas markets.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
15.55 CNY
Average target price
17.75 CNY
Spread / Average Target
+14.15%
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 000739 Stock
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW